Silver/poly (lactic acid) nanocomposites: preparation, characterization, and antibacterial activity.
In this study, antibacterial characteristic of silver/poly (lactic acid) nanocomposite (Ag/PLA-NC) films was investigated, while silver nanoparticles (Ag-NPs) were synthesized into biodegradable PLA via chemical reduction method in diphase solvent. Silver nitrate and sodium borohydride were respectively used as a silver precursor and reducing agent in the PLA, which acted as a polymeric matrix and stabilizer. Meanwhile, the properties of Ag/PLA-NCs were studied as a function of the Ag-NP weight percentages (8, 16, and 32 wt% respectively), in relation to the use of PLA. The morphology of the Ag/PLA-NC films and the distribution of the Ag-NPs were also characterized. The silver ions released from the Ag/PLA-NC films and their antibacterial activities were scrutinized. The antibacterial activities of the Ag/PLA-NC films were examined against Gram-negative bacteria (Escherichia coli and Vibrio parahaemolyticus) and Gram-positive bacteria (Staphylococcus aureus) by diffusion method using Muller-Hinton agar. The results indicated that Ag/PLA-NC films possessed a strong antibacterial activity with the increase in the percentage of Ag-NPs in the PLA. Thus, Ag/PLA-NC films can be used as an antibacterial scaffold for tissue engineering and medical application.
Shameli
Kamyar
K
Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Selangor, Malaysia. kamyarshameli@gmail.com
Ahmad
Mansor Bin
MB
Yunus
Wan Md Zin Wan
WM
Ibrahim
Nor Azowa
NA
Rahman
Russly Abdul
RA
Jokar
Maryam
M
Darroudi
Majid
M
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004926:Escherichia coli / Q000187:drug effects; D053768:Metal Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D008826:Microbial Sensitivity Tests; D046529:Microscopy, Electron, Transmission; D053761:Nanocomposites / Q000737:chemistry* / Q000648:ultrastructure; D050997:Nanomedicine; D010316:Particle Size; D012834:Silver / Q000008:administration & dosage / Q000494:pharmacology*; D013053:Spectrophotometry; D017550:Spectroscopy, Fourier Transform Infrared; D013211:Staphylococcus aureus / Q000187:drug effects; D054457:Tissue Scaffolds; D014736:Vibrio parahaemolyticus / Q000187:drug effects; D014961:X-Ray Diffraction
D000900:Anti-Bacterial Agents; D012834:Silver